Bevacizumab in advanced NSCLC: Chemotherapy partners and duration of use

Ryan D. Gentzler, Sarah E. Yentz, Jyoti Dinker Patel

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Opinion statement: Bevacizumab is an effective targeted therapy with demonstrated survival benefits for many patients with advanced nonsquamous non-small cell lung cancer (NSCLC). Some patient populations are at higher risk for bleeding complications and bevacizumab should be avoided, but advanced age should not be used as the sole exclusion criterion for use. Bevacizumab is generally a well-tolerated therapy that can be safely given in combination with multiple chemotherapy agents in the induction and maintenance phases of therapy. The optimal maintenance strategy is yet to be determined and is the focus of ongoing trials, such as ECOG 5508. Early use of bevacizumab in the adjuvant setting and continued use in the second-line setting are being investigated in current clinical trials.

Original languageEnglish (US)
Pages (from-to)595-609
Number of pages15
JournalCurrent Treatment Options in Oncology
Issue number4
StatePublished - Dec 1 2013


  • Bevacizumab
  • Maintenance
  • Metastatic
  • Non-small cell lung cancer
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)


Dive into the research topics of 'Bevacizumab in advanced NSCLC: Chemotherapy partners and duration of use'. Together they form a unique fingerprint.

Cite this